Cargando…

Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes

BACKGROUND: Previous studies have reported that global longitudinal strain (GLS) is reduced in patients with hypertrophic cardiomyopathy (HCM) while left ventricular ejection fraction (LVEF) is normal. Our aim was to assess GLS in individuals with HCM mutations without hypertrophic changes and to de...

Descripción completa

Detalles Bibliográficos
Autores principales: van Velzen, H. G., Schinkel, A. F. L., van Grootel, R. W. J., van Slegtenhorst, M. A., van der Velden, J., Strachinaru, M., Michels, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393574/
https://www.ncbi.nlm.nih.gov/pubmed/30680638
http://dx.doi.org/10.1007/s12471-019-1226-5
_version_ 1783398721692631040
author van Velzen, H. G.
Schinkel, A. F. L.
van Grootel, R. W. J.
van Slegtenhorst, M. A.
van der Velden, J.
Strachinaru, M.
Michels, M.
author_facet van Velzen, H. G.
Schinkel, A. F. L.
van Grootel, R. W. J.
van Slegtenhorst, M. A.
van der Velden, J.
Strachinaru, M.
Michels, M.
author_sort van Velzen, H. G.
collection PubMed
description BACKGROUND: Previous studies have reported that global longitudinal strain (GLS) is reduced in patients with hypertrophic cardiomyopathy (HCM) while left ventricular ejection fraction (LVEF) is normal. Our aim was to assess GLS in individuals with HCM mutations without hypertrophic changes and to determine its prognostic value for the development of HCM. METHODS AND RESULTS: This retrospective case-control and cohort study included 120 HCM mutation carriers and 110 controls. GLS and LVEF were assessed with Tomtec Imaging software. Age, gender, and body surface area were similar in mutation carriers and controls. Compared to controls, mutation carriers had a higher maximal wall thickness (9 ± 2 vs 8 ± 2 mm, p < 0.001), higher LVEF (60 ± 5 vs 58 ± 4%, p < 0.001) and higher GLS (−21.4 ± 2.3% vs −20.3 ± 2.2%, p < 0.001). The GLS difference was observed in the mid-left ventricle (−21.5 ± 2.5% vs −19.9 ± 2.5%, p < 0.001) and the apex (−24.1 ± 3.5% vs −22.1 ± 3.4%, p < 0.001), but not in the base of the left ventricle (−20.0 ± 3.3% vs −20.0 ± 2.6%, p = 0.9). Echocardiographic follow-up was performed in 80 mutation carriers. During 5.6 ± 2.9 years’ follow-up, 13 (16%) mutation carriers developed HCM. Cox regression analysis showed age (hazard ratio (HR) 1.08, p = 0.01), pathological Q wave (HR 8.56; p = 0.01), and maximal wall thickness (HR 1.94; p = 0.01) to be independent predictors of the development of HCM. GLS was not predictive of the development of HCM (HR 0.78, p = 0.07). CONCLUSION: GLS is increased in HCM mutation carriers without hypertrophic changes. GLS was of no clear prognostic value for the development of HCM during follow-up, in contrast to age, pathological Q waves and maximal wall thickness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12471-019-1226-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6393574
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bohn Stafleu van Loghum
record_format MEDLINE/PubMed
spelling pubmed-63935742019-03-15 Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes van Velzen, H. G. Schinkel, A. F. L. van Grootel, R. W. J. van Slegtenhorst, M. A. van der Velden, J. Strachinaru, M. Michels, M. Neth Heart J Original Article BACKGROUND: Previous studies have reported that global longitudinal strain (GLS) is reduced in patients with hypertrophic cardiomyopathy (HCM) while left ventricular ejection fraction (LVEF) is normal. Our aim was to assess GLS in individuals with HCM mutations without hypertrophic changes and to determine its prognostic value for the development of HCM. METHODS AND RESULTS: This retrospective case-control and cohort study included 120 HCM mutation carriers and 110 controls. GLS and LVEF were assessed with Tomtec Imaging software. Age, gender, and body surface area were similar in mutation carriers and controls. Compared to controls, mutation carriers had a higher maximal wall thickness (9 ± 2 vs 8 ± 2 mm, p < 0.001), higher LVEF (60 ± 5 vs 58 ± 4%, p < 0.001) and higher GLS (−21.4 ± 2.3% vs −20.3 ± 2.2%, p < 0.001). The GLS difference was observed in the mid-left ventricle (−21.5 ± 2.5% vs −19.9 ± 2.5%, p < 0.001) and the apex (−24.1 ± 3.5% vs −22.1 ± 3.4%, p < 0.001), but not in the base of the left ventricle (−20.0 ± 3.3% vs −20.0 ± 2.6%, p = 0.9). Echocardiographic follow-up was performed in 80 mutation carriers. During 5.6 ± 2.9 years’ follow-up, 13 (16%) mutation carriers developed HCM. Cox regression analysis showed age (hazard ratio (HR) 1.08, p = 0.01), pathological Q wave (HR 8.56; p = 0.01), and maximal wall thickness (HR 1.94; p = 0.01) to be independent predictors of the development of HCM. GLS was not predictive of the development of HCM (HR 0.78, p = 0.07). CONCLUSION: GLS is increased in HCM mutation carriers without hypertrophic changes. GLS was of no clear prognostic value for the development of HCM during follow-up, in contrast to age, pathological Q waves and maximal wall thickness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12471-019-1226-5) contains supplementary material, which is available to authorized users. Bohn Stafleu van Loghum 2019-01-24 2019-03 /pmc/articles/PMC6393574/ /pubmed/30680638 http://dx.doi.org/10.1007/s12471-019-1226-5 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
van Velzen, H. G.
Schinkel, A. F. L.
van Grootel, R. W. J.
van Slegtenhorst, M. A.
van der Velden, J.
Strachinaru, M.
Michels, M.
Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
title Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
title_full Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
title_fullStr Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
title_full_unstemmed Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
title_short Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
title_sort five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393574/
https://www.ncbi.nlm.nih.gov/pubmed/30680638
http://dx.doi.org/10.1007/s12471-019-1226-5
work_keys_str_mv AT vanvelzenhg fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges
AT schinkelafl fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges
AT vangrootelrwj fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges
AT vanslegtenhorstma fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges
AT vanderveldenj fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges
AT strachinarum fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges
AT michelsm fiveyearprognosticsignificanceofgloballongitudinalstraininindividualswithahypertrophiccardiomyopathygenemutationwithouthypertrophicchanges